Expanded access to Paxlovid with pharmacist prescribing in the US.
With the intention of expanding access to oral Paxlovid (nirmatrelvir/ritonavir) COVID-19 antiviral treatment from Pfizer, the FDA has authorized pharmacists to prescribe Paxlovid under certain conditions.
Paxlovid has emerged as the leading treatment to prevent COVID-19 from worsening in patients at high risk of severe outcomes, but prescribing restrictions and the logistics of getting the treatment to patients within five days after symptoms begin have limited use of the treatment.
The FDA's Center for Drug Evaluation and Research (CDER) announced the revision to the emergency use authorization (EUA) for Paxlovid on 6 July 2022
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.